Kyiv Investment Group to spend $50 million in Russian blood preparations and recombinant drugs production
Kyiv Investment Group, one of Ukraine’s largest investment groups, has announced its plans to invest up to $50 million in the building of a plant for the production of blood preparations and recombinant drugs in Russia’s Kaluga region.
The new plant, the planned capacity of which was not disclosed, will be built in the Vorsino industrial park.
Russian analysts believe that the project can bring significant profits, as, according to DSM Group, one of Russia’s largest analyst agencies in the field of pharmaceutics, sales of immunoglobulin preparations in Russia are steadily growing and last year amounted to about 2.5 billion roubles ($76.66 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze